AI Summary
Dr. Griffin provides a clinical update on respiratory syncytial virus, RSV vaccine Abrysvo, monoclonal anti-RSV antibody nirsevimab, influenza, SARS-CoV-2 statistics, variants, self-testing accuracy, N95 masks, long COVID prevalence, CDC guidelines, viral rebound myth, paxlovid payment, steroids, convalescent plasma, long COVID incidence challenges, fatiguing illness predictors, and respiratory pathologies linked to SARS-C0V-2 infection.
In his weekly clinical update, Dr. Griffin reviews recent statistics on the circulation of respiratory syncytial virus before discussing uptake of the RSV vaccine Abrysvo or the monoclonal anti-RSV antibody nirsevimab to prevent severe disease following RSV infection in infants 8 months or younger before going over this week’s influenza virus and SARS-CoV-2 virus statistics, including all circulating variants in the US, examines if self-testing is more accurate than clinician administered Binax rapid diagnostic tests for SARS-CoV-2 infection, if N95 masks need a yearly fitting, how SARS-CoV-2 vaccination impacts the prevalence of long COVID, reviews the CDC guidelines for quarantine/ isolation following SARS-CoV-2 infection, continues to dispel the myth of viral rebound, how to pay for paxlovid, when to use steroids and the benefits of convalescent plasma, why determining the exact number of long COVID incidences is challenging, how the incidence and predictors for fatiguing illness following SARS-CoV-2 infection may used to reenforce the need for public health actions to prevent virus infection and the risks of respiratory pathologies including lung cancer associate with SARS-C0V-2 infection.
Click arrow to play
Download TWiV 1090 (26 MB .mp3, 36 min)
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode
- Respiratory disease surveillance (CDC)
- RSV surveillance (CDC)
- RSV national trend (CDC)
- RSV vaccination stats (CIDRAP)
- Abrysvo vaccine stats (Axios)
- RSV vaccination dashboard (CDC)
- Influenza/flu surveillance (CDC)
- Influenza/flu map (CDC)
- COVID-19 hospital admissions (CDC)
- COVID-19 national trend (CDC)
- COVID-19 wastewater testing (biobot)
- Variant tracker (CDC)
- Variant hospital admissions (CDC)
- Who is more accurate the clinician or the self for BinaxNow rapid testing (ASM Spectrum)
- Annual N95 fitting (Infection Control and Hospital Epidemiology)
- How vaccination impacts long COVID prevalence (Annals of Epidemiology)
- CDC Quarantine guidelines (CDC)
- To rebound or to not rebound (MMWR)
- Know your COVID-19 tools (ESMED)
- How to pay for Paxlovid (PAXCESS)
- Molnupiravir safety and efficacy (JMV)
- Convalescent plasma recommendation for immunocompromised (IDSociety)
- Steroids, dexamethasone at the right time (OFID)
- Anticoagulation guidelines (hematology.org)
- Long COVID in adults (MMWR)
- Estimating and predicting fatiguing illness after SARS-CoV-2 infection (EIS)
- Long term risks of respiratory disease following SARS-CoV-2 infection (eClinical Medicine)
- Contribute to our ASTMH fundraiser at PWB
- Letters read on TWiV 1080
- Dr. Griffin’s COVID treatment summary (pdf)
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to daniel@microbe.tv
The post TWiV 1090: Clinical update with Dr. Daniel Griffin first appeared on This Week in Virology.